Actively Recruiting
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Led by University of Washington · Updated on 2026-05-04
60
Participants Needed
1
Research Sites
174 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.
CONDITIONS
Official Title
Repurposing Valsartan May Protect Against Pulmonary Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, age 18 to 80
- Diagnosed with WHO Group 1 Pulmonary Arterial Hypertension
- NYHA Functional Class II, III, or IV at screening
- Right heart catheterization within five years showing mean pulmonary arterial pressure 325 mmHg, occlusion pressure 315 mmHg, and resistance 3 wood units
- If mean pulmonary arterial pressure is 325 mmHg and occlusion pressure is 15-20 mmHg, pulmonary vascular resistance 9 wood units and treatment with PAH-specific therapy are required
- Able to walk at least 50 meters with or without a walking aid
You will not qualify if you...
- Pregnant or lactating
- Non-group 1 pulmonary hypertension or veno-occlusive disease
- History of interstitial lung disease unless collagen vascular disease with lung function 360% in past 12 months
- Received or will receive investigational drug or device within 30 days or during study
- Use of ACE inhibitors, ARB, or ARNI within 30 days of randomization
- Left-sided heart disease with ejection fraction less than 40%
- Any other serious illness or lab abnormality posing risk or affecting study data
- Expected survival less than 1 year due to other diseases
- Allergy or angioedema from ACE inhibitors
- Potassium level over 5 mEq/L or serum creatinine over 2 mg/dL at screening
- Systolic blood pressure less than 90 mmHg at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Washington Medical Center
Seattle, Washington, United States, 98195
Actively Recruiting
Research Team
L
Laurie Hogl, RRT
CONTACT
N
Nancy Liston, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here